Savara Pharmaceuticals
#6654
Rank
$528.26M
Marketcap
United States
Country
Mr. Matthew Pauls (Chairman & CEO)
Mr. David L. Lowrance CPA (CFO & Sec.)
Ms. Kate McCabe (Sr. VP of Legal Affairs)
Summary
History
Savara was founded in 2008 by clinical-stage, specialty pharmaceutical companies focused on the development and commercialization of innovative therapies for rare respiratory diseases. The company has raised over $100 million in venture capital and has multiple products in clinical development. In 2012, Savara entered into an exclusive licensing agreement with Alexion Pharmaceuticals, to develop and commercialize their drug, Aravive, for the treatment of idiopathic pulmonary fibrosis.
Mission
Vision
Key Team
Ms. Anne Erickson (Sr. VP & Head of Global Bus. Operations)
Brian Maurer (Head of Clinical Operations)
Mr. Charles LaPree (Sr. VP of Global Regulatory Affairs & Quality Assurance)
Dr. Peter Clarke Ph.D. (Exec. VP of Global Technical Operations)
Dr. Raymond Dennis Pratt FACP, M.D. (Chief Medical Officer)
Recognition and Awards
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Mr. Matthew Pauls (Chairman & CEO)
Mr. David L. Lowrance CPA (CFO & Sec.)
Ms. Kate McCabe (Sr. VP of Legal Affairs)